Advanced searches left 3/3

Naloxone - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 13 September 2022

* If you want to update the article please login/register

The Impact of Co-Dispensing Naloxone to Patients Prescribed Chronic Opioid Therapy

Patients are supposed to be able to recover opioid overdose prevention under the terms of a standing order, according to the project's goal. Participants in chronic opioid therapy that use randomized pharmacies will be invited to complete and risk studies at the baseline and the follow-up. Patients who use randomized pharmacies will also be monitored in the electronic health record for secondary outcomes: naloxone dispensings, changes in opioid dosage, persistent urine toxicology findings, and overdose events will be monitored.

Source link: https://clinicaltrials.gov/ct2/show/NCT03337100


The Impact of a Web-Based Naloxone Intervention Under Standing Orders to Patients Prescribed Chronic Opioid Therapy

This is a population-randomized analysis of a targeted, web-based overdose prevention and naloxone therapy for patients on continuous opioid therapy. Adults prescribed continuing opioid therapy will be identified in the electronic health record, which has been marketed and screened for participation. Patients are also urged to buy naloxone from a pharmacy under standing orders in this video. The most important result is drug use behaviour. Patients will also be monitored in the electronic health record for naloxone dispensings, changes in opioid dosage, aberrant urine toxicology findings, and overdose events will be monitored.

Source link: https://clinicaltrials.gov/ct2/show/NCT03337009


Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on Buprenorphine/Naloxone

This clinical trial is designed to determine the safety of psilocybin in adult patients with opioid use disorder who are also taking buprenorphine/naloxone simultaneously. Participants in this case will be adults with a drug use disorder who have been reported to be stable on a daily buprenorphine/naloxone dose. Each participant will ingest 1 oral dose of psilocybin after psychological assessment and at least six hours of preparatory and preparation for the psilocybin dosing, model, and location. Following eight hours of observation in the dosing room, the participant will be held overnight in the hospital Clinical Research Unit and complete an integration session with a psychologist before returning home. With the same length of observation, the participant will receive his second oral dose of psilocybin about four weeks after the first dose.

Source link: https://clinicaltrials.gov/ct2/show/NCT04161066


A Survey of High Risk Patient and Caregiver Attitudes and Beliefs Regarding the Prescription of Intranasal Naloxone Spray for Opioid Overdose

To find out what percentage of high risk patients who receive intranasal naloxone prescriptions are going to be helpful to them. To determine the relationship between high risk patients' and their caregivers' lives and their belief that a prescription for intranasal naloxone is beneficial to patients.

Source link: https://clinicaltrials.gov/ct2/show/NCT04129138

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions